Compare Alexandria Real Estate Equities Inc (ARE) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Crispr Therapeutics AG — how do they compare? Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.28B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.23B). The key difference: Alexandria Real Estate Equities Inc is the larger of the two by market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ARE | CRSP | |
|---|---|---|
Market Cap | $8.28B | $5.23B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $76.78 |
52-Week Low | $40.41 | $44.34 |
Enterprise Value | $20.98B | $3.65B |
Dividend Yield | 5.99% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
